Oppenheimer Reiterates Outperform on Tarsus Pharmaceuticals, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raised the price target from $61 to $63.
August 09, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Tarsus Pharmaceuticals and raised the price target from $61 to $63.
The reiteration of an Outperform rating and the increase in the price target from $61 to $63 by a reputable analyst is likely to positively impact the stock price of Tarsus Pharmaceuticals in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100